OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 03:47:15 2024-07-11 pm EDT | Pre-market 02:12:36 am | |||
| 14.54 EUR | +0.69% |
|
14.95 | +2.82% |
| Current month | +12.10% | ||
| 1 month | +3.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 14.54 | +0.69% |
| 24-07-10 | 14.44 | +2.12% |
| 24-07-09 | 14.14 | +2.39% |
| 24-07-08 | 13.81 | +6.31% |
| 24-07-05 | 12.99 | +1.25% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 03:47 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB4JA7 |
| ISIN | DE000JB4JA74 |
| Date issued | 2023-10-16 |
| Strike | 334.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.75 € |
|---|---|
| Lowest since issue | 2.86 € |
| Spread | 0.5 € |
| Spread % | 3.29% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
492.1
USD
Average target price
473.1
USD
Spread / Average Target
-3.87%
- Stock Market
- Certificates
- Certificat
